Key Takeaways
- ResMed reported adjusted diluted earnings per share of $1.95 for its fiscal third quarter, surpassing analyst estimates of $1.80.
- The company's shares surged by over 8% in early trading, reaching an intraday high of $225 following the robust earnings announcement.
- This strong performance reinforces ResMed's dominant position in the sleep and respiratory care market, signaling sustained growth for investors.
- Revenue climbed 15% year-over-year to $1.25 billion, exceeding projections of $1.20 billion, driven by device sales.
- Management raised its full-year revenue guidance to a range of $4.95 billion to $5.05 billion, up from $4.8 billion to $4.9 billion.
ResMed Exceeds Expectations on Device Sales Surge
ResMed Inc. ($RMD) reported adjusted diluted earnings per share of $1.95 for the third quarter of fiscal year 2024, significantly exceeding the consensus analyst estimate of $1.80. This robust performance was underpinned by a 15% year-over-year revenue increase to $1.25 billion, surpassing expectations of $1.20 billion, primarily fueled by surging demand for its sleep apnea devices and masks. Device sales specifically climbed 18% year-over-year to $750 million, while masks and accessories grew 10% to $500 million.
The strong financial results immediately propelled ResMed shares higher, with the stock opening at $220 and quickly climbing to an intraday high of $225 in early trading, an 8% increase from its previous close of $203.70. Trading volume spiked to nearly three times its 30-day average, indicating strong investor confidence and a significant shift in market sentiment towards the medical device manufacturer.
Market Impact
ResMed's market capitalization expanded by approximately $3 billion in the wake of the earnings release, pushing its valuation past $32 billion. The stock's intraday high of $225 marked its highest level since December 2023, signaling a potential break from recent consolidation and a renewed upward trend. This upward movement represents one of the largest single-day percentage gains for $RMD in the past 12 months, reflecting the market's positive reaction to both the earnings beat and the upward revision of full-year guidance.
The healthcare technology sector, particularly medical device manufacturers, saw a modest uplift, with the broader S&P 500 Healthcare Sector ($XLV) gaining 0.5% in sympathy. Competitors in the respiratory care space, such as Fisher & Paykel Healthcare ($FPH.NZ) and Koninklijke Philips NV ($PHG), also experienced minor positive spillover, though their gains were less pronounced than ResMed's. Investors appear to be re-evaluating the growth prospects within the sleep and respiratory disorder market, with ResMed solidifying its leadership position.
What Analysts Are Saying
Goldman Sachs analysts reiterated their "Buy" rating on ResMed, raising their 12-month price target to $250 from $225, citing the company's "strong execution and expanding market opportunity in connected care." They highlighted the accelerated device sales growth of 18% year-over-year as a key driver, suggesting sustained momentum into the next fiscal year. Their report emphasized the company's operational efficiency, which contributed to a gross margin expansion of 70 basis points to 58.5%.
According to a research note from JP Morgan, "ResMed's third-quarter results underscore the resilience of demand for sleep apnea treatments, particularly given the ongoing market share gains stemming from competitor product recalls." JP Morgan analysts upgraded their price target to $245, emphasizing the company's robust gross margin expansion and effective supply chain management. They noted that the company's net income reached $280 million, demonstrating strong profitability.
Bank of America Merrill Lynch analysts maintained their "Outperform" rating, noting that the company's raised full-year revenue guidance of $4.95 billion to $5.05 billion "provides a clear runway for continued double-digit growth." They pointed to the strong performance in masks and accessories, which grew 10% year-over-year, as a testament to the stickiness of ResMed's ecosystem and its ability to drive recurring revenue streams.
What to Watch
Investors should monitor ResMed's next earnings call, tentatively scheduled for late July, for further insights into its fiscal year 2025 outlook and any updates on new product launches. Continued strength in its connected health platform and subscription services, which saw a 12% increase in recurring revenue, will be a key performance indicator for sustained growth.
Key technical levels for $RMD include immediate resistance at $228, which represents a previous high from early 2024, and strong support at $215, near its 50-day moving average. A decisive break above $228 could signal further upside toward analyst price targets, while a failure to hold $215 might indicate profit-taking pressure.
Potential risk factors include increased competition, particularly from Philips' re-entry into certain markets, and evolving reimbursement policies from major healthcare payers which could impact device adoption rates. Supply chain stability for critical electronic components also remains a factor that could impact future device production and delivery timelines. The company's ability to integrate artificial intelligence into its diagnostic and treatment devices, enhancing patient compliance and outcomes, will be a significant long-term catalyst to observe.
